Xerostomia Therapeutics Market Size Worth USD 2,993.61 Million by 2034 | CAGR: 3.5%

The xerostomia therapeutics market size is expected to reach USD 2,993.61 million by 2034, according to a new study by Polaris Market Research. The report “Xerostomia Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Type (OTC and Prescription), Product, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The xerostomia therapeutics market focuses on products designed to manage dry mouth, a condition where the salivary glands do not produce enough saliva, leading to discomfort and potential oral health issues. The market includes salivary stimulants, substitutes, and oral care products aimed at relieving symptoms and improving oral health. The xerostomia therapeutics market growth is driven by factors such as an aging population, increasing awareness about xerostomia, and the rising prevalence of conditions such as Sjögren's syndrome and side effects from medications.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/xerostomia-therapeutics-market/request-for-sample

Xerostomia therapeutics market opportunities lie in the development of more effective and personalized treatments, with advancements in salivary stimulants and substitutes. Trends include the growing demand for over-the-counter solutions, innovations in oral healthcare products, and the expanding use of digital marketing strategies. Overall, the market demand is expected to grow steadily during the forecast period, fueled by the increasing number of affected individuals, the development of advanced treatment options, and the expanding awareness globally.

Xerostomia Therapeutics Market Report Highlights

• The OTC segment, based on type, dominated the xerostomia therapeutics market share in 2024 due to the widespread availability and affordability of products, offering quick relief for dry mouth symptoms. However, the prescription segment is registering the fastest growth, driven by increasing cases of chronic conditions such as Sjögren's syndrome that require specialized treatments.
• The salivary stimulants segment, by product, dominated the market share in 2024 as they are effective in stimulating saliva production, addressing the core issue of xerostomia.
• North America dominated the xerostomia therapeutics market revenue share in 2024 due to the high prevalence of xerostomia and extensive healthcare access. Asia Pacific is the fastest growing due to increasing awareness of the condition, rising healthcare infrastructure, and a growing elderly population.
• The market comprises several active companies offering various treatments for dry mouth. A few notable participants include Acacia Pharma; Church & Dwight Co., Inc.; Colgate-Palmolive Company; Forward Science; GlaxoSmithKline plc; Hikma Pharmaceuticals PLC; Lupin Pharmaceuticals, Inc.; Mission Pharmacal Company; OraCoat; Parnell Pharmaceuticals, Inc.; Pendopharm; Pfizer Inc.; Recordati Industria Chimica e Farmaceutica S.p.A; Sun Pharmaceutical Industries Ltd.; and Synedgen, Inc.

Polaris Market Research has segmented the xerostomia therapeutics market report on the basis of type, product, and region:

By Type Outlook (Revenue – USD Million, 2020–2034)

• OTC
• Prescription

By Product Outlook (Revenue – USD Million, 2020–2034)

• Salivary Stimulants
• Salivary Substitutes
• Dentifrices

By Regional Outlook (Revenue – USD Million, 2020–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Xerostomia Therapeutics Market Report Scope